18F-FDG-PET/CT用于避免甲状腺不确定结节的无益手术:一项盲法随机对照多中心试验
该双盲随机对照多中心试验纳入132例Bethesda III或IV甲状腺结节患者,随机分为18F-FDG-PET/CT驱动管理组和诊断手术组。PET/CT驱动组无益管理比例为42%,显著低于诊断手术组的83%(p<0.001),避免了40%的良性结节诊断手术。结论认为该策略可安全减少无益手术,但为获得最佳治疗收益应限于非Hürthle细胞结节。
要点
- PET/CT驱动管理组无益管理比例42% vs 诊断手术组83%(p<0.001)。
- PET/CT驱动管理避免了40%的良性结节诊断手术。
- 非Hürthle细胞结节避免手术48%,Hürthle细胞结节仅13%(p=0.02)。
核心结论
- 18F-FDG-PET/CT驱动的诊断流程可改变甲状腺不确定结节的管理实践,准确且肿瘤学安全地减少40%的无益手术。
- 为获得最佳治疗收益,应用应限于非Hürthle细胞结节。
研究设计与样本
- 双盲、随机对照、多中心试验,纳入132例因Bethesda III或IV甲状腺结节计划行诊断性手术的成年甲状腺功能正常患者。
- 患者接受18F-FDG-PET/CT后随机分为PET/CT驱动组或诊断手术组,进行意向性分析,并对非Hürthle细胞和Hürthle细胞结节进行亚组分析。
主要发现
- PET/CT驱动组无益管理比例为42%(38/91,95%CI 32-53%),诊断手术组为83%(34/41,95%CI 68-93%),p<0.001。
- PET/CT驱动管理避免了40%的良性结节诊断手术(25/63,95%CI 28-53%)。
- 非Hürthle细胞结节避免手术48%(23/48,95%CI 33-63%),Hürthle细胞结节避免手术13%(2/15,95%CI 2-40%),p=0.02。
- 监测中的患者未观察到恶性或交界性肿瘤。
- 18F-FDG-PET/CT的敏感性94.1%(80.3-99.3%)、特异性39.8%(30.0-50.2%)、阴性预测值95.1%(83.5-99.4%)、阳性预测值35.2%(25.4-45.9%)、良性呼叫率31.1%(23.3-39.7%)。
关键数值与推荐
- 在PET/CT驱动组,若目标结节视觉上18F-FDG阳性,建议行诊断性手术;若18F-FDG阴性,推荐主动监测。
- 超声监测中结节保持不变时推定为良性。
- 诊断手术组所有患者均按现行指南建议进行预定手术。
临床怎么用
- 对于Bethesda III或IV甲状腺结节,18F-FDG-PET/CT驱动的诊断流程可减少无益的诊断性手术。
- 为获得最佳治疗收益,作者认为应用应限于非Hürthle细胞结节。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the impact of an [18F]FDG-PET/CT-driven diagnostic workup to rule out malignancy, avoid futile diagnostic surgeries, and improve patient outcomes in thyroid nodules with indeterminate cytology. METHODS: In this double-blinded, randomised controlled multicentre trial, 132 adult euthyroid patients with scheduled diagnostic surgery for a Bethesda III or IV thyroid nodule underwent [18F]FDG-PET/CT and were randomised to an [18F]FDG-PET/CT-driven or diagnostic surgery group. In the [18F]FDG-PET/CT-driven group, management was based on the [18F]FDG-PET/CT result: when the index nodule was visually [18F]FDG-positive, diagnostic surgery was advised; when [18F]FDG-negative, active surveillance was recommended. The nodule was presumed benign when it remained unchanged on ultrasound surveillance. In the diagnostic surgery group, all patients were advised to proceed to the scheduled surgery, according to current guidelines. The primary outcome was the fraction of unbeneficial patient management in one year, i.e., diagnostic surgery for benign nodules and active surveillance for malignant/borderline nodules. Intention-to-treat analysis was performed. Subgroup analyses were performed for non-Hürthle cell and Hürthle cell nodules. RESULTS: Patient management was unbeneficial in 42% (38/91 [95% confidence interval [CI], 32-53%]) of patients in the [18F]FDG-PET/CT-driven group, as compared to 83% (34/41 [95% CI, 68-93%]) in the diagnostic surgery group (p < 0.001). [18F]FDG-PET/CT-driven management avoided 40% (25/63 [95% CI, 28-53%]) diagnostic surgeries for benign nodules: 48% (23/48 [95% CI, 33-63%]) in non-Hürthle cell and 13% (2/15 [95% CI, 2-40%]) in Hürthle cell nodules (p = 0.02). No malignant or borderline tumours were observed in patients under surveillance. Sensitivity, specificity, negative and positive predictive value, and benign call rate (95% CI) of [18F]FDG-PET/CT were 94.1% (80.3-99.3%), 39.8% (30.0-50.2%), 95.1% (83.5-99.4%), 35.2% (25.4-45.9%), and 31.1% (23.3-39.7%), respectively. CONCLUSION: An [18F]FDG-PET/CT-driven diagnostic workup of indeterminate thyroid nodules leads to practice changing management, accurately and oncologically safely reducing futile surgeries by 40%. For optimal therapeutic yield, application should be limited to non-Hürthle cell nodules. TRIAL REGISTRATION NUMBER: This trial is registered with ClinicalTrials.gov: NCT02208544 (5 August 2014), https://clinicaltrials.gov/ct2/show/NCT02208544 .
引用
- de Koster EJ, de Geus-Oei LF, Brouwers AH, et al. [18F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial. Eur J Nucl Med Mol Imaging. 2022. PMID: 34981165. doi:10.1007/s00259-021-05627-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。